SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001213900-25-008639 from CERO THERAPEUTICS HOLDINGS, INC. (CERO)

CERO THERAPEUTICS HOLDINGS, INC.
Date: Jan. 31, 2025 · CIK: 0001870404 · Accession: 0001213900-25-008639

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-284007

Date
January 31, 2025
Author
/s/ Chris Ehrlich
Form
CORRESP
Company
CERO THERAPEUTICS HOLDINGS, INC.

Letter

VIA EDGAR Division of Corporation Finance Office of Life Sciences Acceleration Request for Registration Statement on Form S-1 File No. 333-284007 Requested Date: February 3, 2025 Requested Time: 9:15 a.m. Eastern Time

Dear Ladies and Gentlemen,

Pursuant to Rule 461 under the Securities Act of 1933, as amended, CERo Therapeutics Holdings, Inc. hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to February 3, 2025, at 9:15 a.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP (“Goodwin”), request by telephone that such Registration Statement be declared effective at some other time.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin, by calling Jeffrey Letalien at (212) 459-7203. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin, Attention: Jeffrey Letalien, by email at JLetalien@goodwinlaw.com.

If you have any questions regarding this request, please contact Jeffrey Letalien of Goodwin at (212) 459-7203.

Sincerely,
CERo Therapeutics Holdings, Inc.

Show Raw Text
CORRESP
1
filename1.htm

CERo Therapeutics Holdings, Inc.

201 Haskins Way, Suite 230

South San Francisco, CA 94080

January 31, 2025

VIA EDGAR

Division of Corporation Finance

Office of Life Sciences

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

  Re:
  CERo Therapeutics Holdings, Inc.

  Acceleration Request for Registration Statement on Form S-1

  File No. 333-284007

  Requested Date: February 3, 2025

  Requested Time: 9:15 a.m. Eastern Time

Dear Ladies and Gentlemen,

Pursuant to Rule 461 under the Securities Act of
1933, as amended, CERo Therapeutics Holdings, Inc. hereby requests that the effective date of the above-referenced registration statement
(the “Registration Statement”) be accelerated to February 3, 2025, at 9:15 a.m., Eastern Time, or as soon thereafter
as practicable, unless we or our outside counsel, Goodwin Procter LLP (“Goodwin”), request by telephone that such Registration
Statement be declared effective at some other time.

Once the Registration Statement is effective, please
orally confirm the event with our counsel, Goodwin, by calling Jeffrey Letalien at (212) 459-7203. We also respectfully request that a
copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement
be sent to our counsel, Goodwin, Attention: Jeffrey Letalien, by email at JLetalien@goodwinlaw.com.

If you have any questions regarding this request,
please contact Jeffrey Letalien of Goodwin at (212) 459-7203.

    Sincerely,

    CERo Therapeutics Holdings, Inc.

    /s/ Chris Ehrlich

    Chief Executive Officer

  cc:
  Stephen M. Davis, Esq., Goodwin Procter LLP

  Jeffrey A. Letalien, Esq., Goodwin Procter LLP